The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Cruz announces that investors with losses related to Regeneron Pharmaceuticals ... distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...

Regeneron is also embroiled in a securities ... distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. To further protect the integrity ...

In a much-anticipated decision, the First Circuit unanimously ruled the government and relators must prove that a violation ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Biotech stocks may be primed for a long-term bull run. Learn why IBB, XBI, and macro trends like rate cuts make biotech an ...